Literature DB >> 19723361

Diagnosis of hepatitis C virus infection in Scotland's injecting drug user population.

S A McDonald1, S J Hutchinson, P R Mills, S M Bird, C Robertson, J F Dillon, A Springbett, D J Goldberg.   

Abstract

We estimated the extent of undiagnosed hepatitis C virus (HCV) infection in injecting drug users (IDUs) in Scotland. We used record-linkage to determine HCV diagnosis status for 41 062 current/former IDUs attending drug treatment and support services between 1 April 1995 and 31 March 2006; the extent of undiagnosed HCV infection was estimated by comparing the number HCV-diagnosed to the number HCV-infected (estimated from an unlinked anonymous testing survey of 2141 current/former IDUs). In all, 9145 IDUs (22%) were diagnosed HCV antibody-positive since first attendance at drug services (diagnosis rate of 33.6/1000 person-years, 95% CI 32.7-34.4). By 31 March 2006, of the 19 632 current/former IDUs who had attended drug services and were determined to be living with HCV, an estimated 58% (95% CI 45-62) had not been HCV-diagnosed. It is essential that the deployment of resources for identifying at-risk IDUs with a view to offering antiviral therapy is guided by evidence.

Entities:  

Mesh:

Year:  2009        PMID: 19723361     DOI: 10.1017/S0950268809990616

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  6 in total

Review 1.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

Authors:  Mirjana R Jovanovic; Aleksandar Miljatovic; Laslo Puskas; Slobodan Kapor; Dijana L Puskas
Journal:  Front Pharmacol       Date:  2017-06-30       Impact factor: 5.810

3.  Hepatitis C prevalence in Denmark -an estimate based on multiple national registers.

Authors:  Peer Brehm Christensen; Gordon Hay; Peter Jepsen; Lars Haukali Omland; Søren Andreas Just; Henrik Bygum Krarup; Nina Weis; Niels Obel; Susan Cowan
Journal:  BMC Infect Dis       Date:  2012-08-06       Impact factor: 3.090

4.  Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study.

Authors:  Perrine Roux; Daniela Rojas Castro; Khadim Ndiaye; Marie Debrus; Camélia Protopopescu; Jean-Marie Le Gall; Aurélie Haas; Marion Mora; Bruno Spire; Marie Suzan-Monti; Patrizia Carrieri
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

5.  Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors.

Authors:  Simon R White; Sheila M Bird; Elizabeth L C Merrall; Sharon J Hutchinson
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

6.  Scotland's 2009-2015 methadone-prescription cohort: Quintiles for daily dose of prescribed methadone and risk of methadone-specific death.

Authors:  Lu Gao; J Roy Robertson; Sheila M Bird
Journal:  Br J Clin Pharmacol       Date:  2020-07-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.